FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets)

ATTY. DOCKET NO. QA0278 NP APPLICATION NO. 10/773,002 APPLICANT CHEN ET AL. FILING DATE FEBRUARY 5, 2004

Group 1614

| | 1 | TRAUE MARTIN | J.S. RELAT | ED PATENT APPLICATIONS | | | | · <u>·</u> ··· <u>/</u> ··· | |
|----------------------|------------------|------------------------|-----------------------|--|-----------|-------|-----------|-----------------------------|----------------|
| EXAMINER DITTIAL | | DOCUMENT NUMBER | DATE | NAME | Q. | ss | SUBCLAS | S. | FILING DATE |
| | AA | | | | | | | | |
| | AB | *** | | • | | | | | |
| | AC | | | | | | | | |
| | AD | | | | | | | | |
| | AE | | | | | | | | |
| | AF | | | | , | | | | |
| | AG | | | | | | | | |
| | AH | | | | | | | | |
| | Al | | | | | | | | |
| | AJ | | | | | | | 1 | |
| | AK | | | | | | | | |
| | AL | | | • | | | | | |
| | АМ | | | | | | | | |
| | | | U.S. F | PATENT DOCUMENTS | | | | | |
| | | DOCUMENT NUMBER | DATE | NAME | GL/ | uss | SUBCLAS | s | FILING DATE |
| | AN | 6,670,357 | 12/30/03 | Leftheris et al. | <u> </u> | | | | |
| | | | FOREIG | N PATENT DOCUMENTS | . • | | • | | |
| | | DOCUMENT NUMBER | DATE | OFFICE | CLASS | SUE | CLASS | IRA YES | NSLATION NO |
| M | AO | WO 00/71129 | 11/30/00 | PCT | | | | | |
| (W | AP | WO 01/14378 | 3/1/01 | PCT | | | | | |
| M | AQ | WO 02/40486 | 5/23/02 | PCT | | | | | |
| \(\sqrt{\sqrt{\chi}} | AR | WO 03/090912 | 11/6/03 | PCT | | | | | |
| | | | | including Author, Title, Date, Pertine | | | | | |
| | AS | Vol. 10, pp. 883-887 (| riazines. I. 1967) | 5-Sulfanilamido Derivatives and | d Interme | diate | s", J. Me | d. Cl | nem., |
| EXAMIN | IER _V | Balessyl | enor | DATE CONSIDERED | 7 | 12 | 4/0 | 5 | |

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in

conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

FEB 0 2 2005

ATTY. DOCKET NO. **QA0278 NP** APPLICATION NO. 10/773,002 APPLICANT CHEN ET AL. **FILING DATE** FEBRUARY 5, 2004

Group 1614

U.S. PATENT APPLICATION PUBLICATIONS

| MINER TRAL | | TRADEMARTS U.S. | DATE | NAME | CLASS | SUBCLASS | FILING DATE |
|----------------|-----|-----------------|----------|---------------------|-------|----------|----------------|
| q | 2AA | 2002/0065270 | 5/30/02 | Moriarty et al. | | | |
| 1 | 2AB | 2002/0137747 | 9/26/02 | Moriarty et al. | | | |
| ۸ | 2AC | 2003/0139435 | 7/24/03 | Ahmed et al. | | | |
| <u>/</u> | 2AD | 2003/0186982 | 10/2/03 | Godfrey, Jr. et al. | | | |
| M | 2AE | 2003/0186983 | 10/2/03 | Mastalerz et al. | | | |
| W | 2AF | 2003/0232831 | 12/18/03 | Dyckman et al. | | | |
| M | 2AG | 2004/0023992 | 2/5/04 | Das et al. | | • | |
| M | 2AH | 2004/0063707 | 4/1/04 | Bhide et al. | | | |
| W | 2AI | 2004/0063708 | 4/1/04 | Bhide et al. | | | |
| M | 2AJ | 2004/0072832 | 4/15/04 | Bhide et al. | | | |
| N | 2AK | 2004/0077858 | 4/22/04 | Bhide et al. | | | |
| M | 2AL | 2004/0082582 | 4/29/04 | Dyckman et al. | | | |
| Μ | 2AM | 2004/0142931 | 7/22/04 | Vite et al. | | | · |
| \overline{M} | 2AN | 2004/0229877 | 11/18/04 | Leftheris et al. | | | |
| 7 | AO | | | | | | , - |
| | AP | | | | | | |
| | AQ | | | | | | |
| | AR | | | | | | |
| | AS | · | | | | | |
| | AT | | | • | | | |
| | AU | | | | | | - |
| | AV | | | | | · . | |
| | AW | | | | | | |
| | AX | | | | | | |
| • | AY | | | | | | |
| | AZ | | | | | | |

EXAMINER

DATE CONSIDERED

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in *EXAMINER: conformance and not considered. Include a copy of this form with the next communication to applicant.

CASE QA02

his paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Joseph C. Wang

Type or print name

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

CHEN ET AL.

APPLICATION NO: 10/773,002

FILED: FEBRUARY 5, 2004

FOR: PROCESS FOR PREPARING PYRROLOTRIAZINE KINASE

INHIBITORS

Mail Stop Amendment **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(b).

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Some of the listed references were cited in a search report in a corresponding PCT International application. Copies of these references and the search report are enclosed herewith.

Also, copies of the other cited references are enclosed herewith.

Applicants bring to the Examiner's attention the following U.S. patent applications and/or patents having co-pendency with the instant application and assigned to the present assignee:

1/24/05

US Pat. 6,670,357, granted 12/30/03 (Serial No. 10/036,293, filed 11/7/01) US Publ. No. 2002/0065270A1, published 5/30/02 (Serial No. 09/747,195, filed 12/22/00) US Publ. No. 2002/0137747A1 (Serial No. 09/891,750, filed 6/26/01) US Publ. No. 2003/0139435A1 (Serial No. 10/183,179, filed 6/26/02) US Publ. No. 2003/0186982A1, published 10/2/03 (Serial No. 10/289,010, filed 11/6/02) US Publ. No. 2003/0186983A1, published 10/2/03 (Serial No. 10/294,281, filed 11/14/02) US Publ. No. 2003/0232831A1, published 12/18/03 (Serial No. 10/420.445, filed 4/22/03) US Publ. No. 2004/0023992A1, published 2/5/04 (Serial No. 10/440,864, filed 5/19/03) US Publ. No. 2004/0063707A1, published 4/1/04 (Serial No. 10/622,593, filed 7/18/03) US Publ. No. 2004/0063708A1, published 4/1/04 (Serial No. 10/633,997, filed 8/4/03) US Publ. No. 2004/0072832A1, published 4/15/04 (Serial No. 10/623,171, filed 7/18/03) US Publ. No. 2004/0077858A1, published 4/22/04 (Serial No. 10/622,280, filed 7/18/03) US Publ. No. 2004/0082582A1, published 4/29/04 (Serial No. 10/420,399, filed 3/22/03) US Publ. No. 2004/0142931A1, published 7/22/04 (Serial No. 10/736,476, filed 12/15/03) US Publ. No. 2004/0229877A1, published 11/18/04 (Serial No. 10/696,178, filed 10/29/03) US application Serial No. 09/573,829, filed 5/18/00 US application Serial No. 10/678.388, filed 10/3/03 US application Serial No. 10/970,420, filed 10/21/04 US application Serial No. 11/008,719, filed 12/9/04 US application Serial No. 11/019,899, filed 12/22/04 US application Serial No. 11/019,901, filed 12/22/04 US application Serial No. 60/580,194, filed 6/16/04 US application Serial No. 60/584,289, filed 6/30/04 US application Serial No. 60/584,382, filed 6/30/04 US application Serial No. 60/584,768, filed 7/1/04 US application Serial No. 60/600,935, filed 8/12/04 US application Serial No. 60/620,784, filed 10/21/04

In each of the above patents and/or applications, there are described compounds having a pyrrolotriazine core, and/or compounds having p38 inhibitory activity, and/or processes or intermediates for making such compounds.

A copy of the specification, drawings and claims as currently pending is attached for each above-identified co-pending application.

US application Serial No. 60/639,178, filed 12/23/04

<u>PLEASE DO NOT PRINT</u> any of the above information that is not published on any patent resulting from the subject application.

Consideration of each above listed application is earnestly solicited, since unpublished patent applications are contemplated as IDS material; please see 37 CFR §98(a)(2)(iii) and note the last two sentences of MPEP §609(III)(D).

Further, in keeping with MPEP §609, subsec. (III)(C)(2), 2nd para, line 10 to end of the paragraph (especially note lines 18-25), PLEASE RETURN A COPY OF THIS LETTER with the Examiner's initials adjacent to each above listing so that applicant will know that each listed application has been considered, as required by PTO policy.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 609-252-4931

Date: January 31, 2005

Joseph C. Wang Attorney for Applicants